10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Lexaria Bioscience's 10-Year ROIIC % for the quarter that ended in Aug. 2024 was 155.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lexaria Bioscience's 10-Year ROIIC % or its related term are showing as below:
LEXX's 10-Year ROIIC % is ranked better than 89.18% of 1275
companies
in the Biotechnology industry
Industry Median: -33.25
vs LEXX: 155.44
Lexaria Bioscience 10-Year ROIIC % Historical Data
The historical data trend for Lexaria Bioscience's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's 10-Year ROIIC %
For the Biotechnology subindustry, Lexaria Bioscience's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's 10-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's 10-Year ROIIC % falls into.
Lexaria Bioscience 10-Year ROIIC % Calculation
Lexaria Bioscience's 10-Year ROIIC % for the quarter that ended in Aug. 2024 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -5.753 (Aug. 2024) - -0.378 (Oct. 2013) )
/
( 1.246 (Aug. 2024) - 4.704 (Oct. 2013) )
=
-5.375
/
-3.458
=
155.44%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lexaria Bioscience 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 